RegWardenFDA facility compliance records
Recall

Class II — Ulrich Medical USA Inc

Recalling firmULRICH MEDICAL USA, INC.
Registered facilityULRICH MEDICAL USA, INC. (the firm's only registered facility)
ClassificationClass II
StatusTerminated
ReasonSurgical technique was revised to prevent static plate screws blocking mechanisms from disassociating.
ProductuNion Cervical Plate System Product Usage: The uNion Cervical Plate System is intended for anterior fixation of the cervical spine (C2 to Ti). The system is to be used to provide stabilization of the anterior cervical spine as an adjunct to fusion for the treatment of degenerative disc disease (defined as neck pain of discogenic origin with the degeneration of the disc confirmed by history and radiographic studies), spondylolisthesis, trauma (i.e., fractures or dislocations), tumors, spinal stenosis, deformity (i.e., kyphosis, lordosis or scoliosis), pseudarthrosis or failed previous fusio…
Quantity4,854 plates
DistributionUS Nationwide in the states of: AL, AR, AZ, CA, CT, FL, GA, ID, IL, KS, LA, MO, MS, NY, OH, OK, OR, TN, TX, and WI
Initiated2017-03-07
Classified2017-04-25
Terminated2017-11-30
Recall numberZ-1878-2017
InitiationVoluntary: Firm initiated

Source: U.S. FDA via openFDA (opens in a new tab) (device registration & enforcement). Data as of 2026-10-06. Verify this recall record at FDA → (opens in a new tab)

Cite this record

RegWarden. “Class II recall — Ulrich Medical USA Inc (Z-1878-2017).” Compiled from U.S. FDA public records (openFDA; FDA Data Dashboard). Data as of 2026-10-06. https://regwarden.com/recall/76740/

Not open yet

Alerts for ULRICH MEDICAL USA, INC.

Watchlist alerts will email you when FDA publishes a new recall, inspection classification, or warning letter for a facility you follow. They aren't open to the public yet — leave your email and we'll tell you when they are.

Planned

Want a one-page facility brief?

A single-page summary of this facility's registration and recall history for diligence. Not selling it yet — register interest and we'll follow up.